Navigation Links
Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer

GSK Announces Launch of Largest Ever Phase III Clinical Trial in Lung Cancer Treatment

PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC). These data were presented at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, [Abstract No: 7554]. Final trial analysis showed a 27% reduction in the relative risk of cancer recurrence following surgery in patients treated with the MAGE-A3 ASCI, compared to placebo.

"Final results from this trial confirm the positive interim results released last year at ASCO 2006, and support expanded testing of this novel cancer immunotherapy," said Paul A. Bunn Jr., M.D., James Dudley Endowed Professor of Oncology, Professor of Medicine and Director of the University of Colorado Cancer Center, Aurora, Colorado. "This approach represents a potentially momentous shift in the cancer treatment paradigm. I believe we have only just scratched the surface of what is possible and look forward to seeing the results of the Phase III trial in due course."

Based on these encouraging data, GSK also announced today the opening of patient recruitment to the randomized and controlled Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment. MAGE-A3 ASCI will be evaluated as adjuvant therapy in about 2,270 MAGE-A3 positive patients with completely resected stage IB, II or IIIA NSCLC.

GSK's ASCIs aim to stimulate the patient's own immune response to identify and attack cancer cells in a highly specific manner. This novel cancer immunotherapy is developed using tumor specific antigens, delivered as highly puri
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
3. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
4. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:4/1/2015)... ATLANTA , April 1, 2015  The ... medication, and dietary supplements to treat attention-deficit/hyperactivity disorder ... than one half of children with ADHD were ... Centers for Disease Control and Prevention (CDC) study, ... Health Care Needs," published today in The ...
(Date:4/1/2015)... NEW YORK , April 1, 2015  The ... ("ASPX" or the "Company") by Teva Pharmaceutical Industries ("Teva") ... action, shareholder rights law firm.  The investigation focuses on ... law by the Board of Directors of ASPX for ... 30, 2015, the Company announced a definitive agreement for ...
(Date:4/1/2015)... 1, 2015 In what is a first formal ... leading global medical research organization -- are co-organizing the ... April 19-20 during the MEDTEC China South 2015 exhibition at ... is to assist Chinese medical device manufacturers in going abroad. ... convene this conference in China . Furthermore, ...
Breaking Medicine Technology:CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 2CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 3CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 4WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2MEDTEC & NAMSA Co-organize BPMDS Symposium China 2MEDTEC & NAMSA Co-organize BPMDS Symposium China 3
... product, Velocity 8.0, took the top spot in Forrester ... company surpassed market giants including Google, Microsoft and IBM ... good" rating in each dimension evaluated.  But when it ... on its laurels.  It sells value. ...
... Inc. (OTCBB: PMBS) announced today that LipiGesic M, their ... the treatment of migraine headaches, is now available for ... the United States. With the addition of over 7,000 ... stores nationwide. "We are pleased to now ...
Cached Medicine Technology:Combining a Great Product With a Winning Sales Strategy is a Formula for Success in Today's Market 2Combining a Great Product With a Winning Sales Strategy is a Formula for Success in Today's Market 3PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States 2
(Date:4/2/2015)... Atlanta, Georgia (PRWEB) April 02, 2015 ... continued the Lunch Seminar Series on March 30th ... Director of PartnerTech Inc. , a leading provider ... ‘Total Cost Thinking: Defining Total Cost vs. Piece ... late-stage configuration, agile supply chain service and other ...
(Date:4/2/2015)... “ SmartenFit ” was featured on NewsWatch ... at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... for a sustainable healthy lifestyle. , Health and fitness apps ... new application that covers health from a different angle. The ...
(Date:4/2/2015)... April 02, 2015 Zapable - a ... with a quick and easy means for creating professional ... week creating a buzz of excitement throughout the Internet ... the attention of HonestyFirstReviews.com’s Tiffany Hendricks, prompting her to ... Andrew and Chris Fox's new Zapable software ...
(Date:4/2/2015)... April 02, 2015 As spring weather ... gets its start! Runners have been putting in the ... start racing. Zensah®, a premium compression apparel brand, is ... the athletes are benefiting from compression in ... a Miami-based company, committed to using the best fabrics ...
(Date:4/2/2015)... 02, 2015 Grab your favorite latte or ... of the hottest trends with the all-new, half-hour debut of ... 8th at 7:00 AM ET/PT, 6:00 AM CT, and 5:00 ... and marketing and product strategist Forbes Riley, Forbes Living ... as well as entrepreneurs, inventors, and innovators whose creations are ...
Breaking Medicine News(10 mins):Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 2Health News:Georgia Tech Manufacturing Institute Lunch Series Continues with Gary Bruce of PartnerTech 3Health News:An Application for Long Term Sustainable Lifestyle Change Was Featured on NewsWatch Television 2Health News:Zapable - Review Examining Andrew and Chris Fox’s App Building Software System Released 2Health News:Zensah® Partners With Austin Track Club 2Health News:Zensah® Partners With Austin Track Club 3Health News:Forbes Living Showcases Trendsetters on Discovery Channel Transponder 2Health News:Forbes Living Showcases Trendsetters on Discovery Channel Transponder 3
... are more susceptible to developing disorders like addiction and ... Jan. 16 in the Proceedings of the National ... led by Bita Moghaddam, coauthor of the paper and ... School of Arts and Sciences. She and coauthor David ...
... University School of Medicine have used an innovative mathematical technique ... will be. The discovery, which in this case concerned bladder ... analysis of cancer risk and better treatment of the disease. ... Proceedings of the National Academy of Sciences . This ...
... HealthDay Reporter , TUESDAY, Jan. 17 (HealthDay News) -- ... from chronic obstructive pulmonary disease (COPD), according to a new ... the two main forms of COPD, and many sufferers have ... Since most COPD patients are vitamin D deficient and ...
... Reporter , MONDAY, Jan. 16 (HealthDay News) -- Teenage girls ... develop acne than their normal-weight peers, a new Norwegian survey ... body mass index (BMI, a ratio of weight to height), ... condition among teens. Teens, responses to questionnaires focusing on ...
... , MONDAY, Jan. 16 (HealthDay News) -- Some pediatricians ... them on medication for attention-deficit hyperactivity disorder, new research ... shows it isn,t really necessary. Several years ago, ... children and adults taking stimulants to treat ADHD caused ...
... , MONDAY, Jan. 16 (HealthDay News) -- ... cancer melanoma among white Americans appear to be limited ... found. The findings reveal a widening education-related disparity ... early-detection strategies to effectively target high-risk, low-educated whites, the ...
Cached Medicine News:Health News:Adolescents' brains respond differently than adults' when anticipating rewards 2Health News:Stanford computer algorithm used to identify bladder cancer marker 2Health News:Stanford computer algorithm used to identify bladder cancer marker 3Health News:Vitamin D Won't Help Most COPD Patients: Study 2Health News:Vitamin D Won't Help Most COPD Patients: Study 3Health News:Overweight Teen Girls May Have Higher Acne Risk 2Health News:Overweight Teen Girls May Have Higher Acne Risk 3Health News:Pediatricians Split on Heart Tests Before Kids' ADHD Meds 2Health News:Pediatricians Split on Heart Tests Before Kids' ADHD Meds 3Health News:Drop in Melanoma Deaths Limited to Educated Whites: Study 2
... With just a single size, the Sierra ... Its unique design provides the comfort and motion ... confident you will get the right size for ... And, since the single size and compact design ...
... effective immobilization of the cervical and upper ... that makes it well tolerated by patients. ... going from a stand-alone cervical collar, to ... a four-post orthosis. For these reasons, the ...
... Universal Torso Shoulder Immobilizer A ... 3/8" foam with contact closure. ... posteriorly. Movable wrist cuff. Plastic ... strap. Shoulder strap may adjust ...
... AC Sport Brace is designed for the ... III acromioclavicular separations. Using a pre-inflated aircell, ... the acromioclavicular joint while supporting the arm ... with each AC Sport Brace for additional ...
Medicine Products: